268 related articles for article (PubMed ID: 16474399)
1. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors.
Teague RM; Sather BD; Sacks JA; Huang MZ; Dossett ML; Morimoto J; Tan X; Sutton SE; Cooke MP; Ohlén C; Greenberg PD
Nat Med; 2006 Mar; 12(3):335-41. PubMed ID: 16474399
[TBL] [Abstract][Full Text] [Related]
2. TLR2 engagement on memory CD8(+) T cells improves their cytokine-mediated proliferation and IFN-gamma secretion in the absence of Ag.
Cottalorda A; Mercier BC; Mbitikon-Kobo FM; Arpin C; Teoh DY; McMichael A; Marvel J; Bonnefoy-Bérard N
Eur J Immunol; 2009 Oct; 39(10):2673-81. PubMed ID: 19634192
[TBL] [Abstract][Full Text] [Related]
3. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.
Hervas-Stubbs S; Mancheño U; Riezu-Boj JI; Larraga A; Ochoa MC; Alignani D; Alfaro C; Morales-Kastresana A; Gonzalez I; Larrea E; Pircher H; Le Bon A; Lopez-Picazo JM; Martín-Algarra S; Prieto J; Melero I
J Immunol; 2012 Oct; 189(7):3299-310. PubMed ID: 22925929
[TBL] [Abstract][Full Text] [Related]
4. IL-15 is critical for the maintenance and innate functions of self-specific CD8(+) T cells.
Itsumi M; Yoshikai Y; Yamada H
Eur J Immunol; 2009 Jul; 39(7):1784-93. PubMed ID: 19544306
[TBL] [Abstract][Full Text] [Related]
5. The immunologic function of 1B2+ double negative (CD4-CD8-) T cells in the 2C transgenic mouse.
Margenthaler JA; Flye MW
J Surg Res; 2005 Jun; 126(2):160-6. PubMed ID: 15919414
[TBL] [Abstract][Full Text] [Related]
6. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.
Overwijk WW; Theoret MR; Finkelstein SE; Surman DR; de Jong LA; Vyth-Dreese FA; Dellemijn TA; Antony PA; Spiess PJ; Palmer DC; Heimann DM; Klebanoff CA; Yu Z; Hwang LN; Feigenbaum L; Kruisbeek AM; Rosenberg SA; Restifo NP
J Exp Med; 2003 Aug; 198(4):569-80. PubMed ID: 12925674
[TBL] [Abstract][Full Text] [Related]
7. Treatment with soluble interleukin-15Ralpha exacerbates intracellular parasitic infection by blocking the development of memory CD8+ T cell response.
Khan IA; Moretto M; Wei XQ; Williams M; Schwartzman JD; Liew FY
J Exp Med; 2002 Jun; 195(11):1463-70. PubMed ID: 12045244
[TBL] [Abstract][Full Text] [Related]
8. CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function.
Ohlén C; Kalos M; Cheng LE; Shur AC; Hong DJ; Carson BD; Kokot NC; Lerner CG; Sather BD; Huseby ES; Greenberg PD
J Exp Med; 2002 Jun; 195(11):1407-18. PubMed ID: 12045239
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy.
Mueller K; Schweier O; Pircher H
Eur J Immunol; 2008 Oct; 38(10):2874-85. PubMed ID: 18825743
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effect of lymphotactin and interferon gamma-inducible protein-10 transgene expression in T-cell localization and adoptive T-cell therapy of tumors.
Huang H; Xiang J
Int J Cancer; 2004 May; 109(6):817-25. PubMed ID: 15027114
[TBL] [Abstract][Full Text] [Related]
12. IL-15 promotes survival but not effector function differentiation of CD8+ TCRalphabeta+ intestinal intraepithelial lymphocytes.
Lai YG; Gelfanov V; Gelfanova V; Kulik L; Chu CL; Jeng SW; Liao NS
J Immunol; 1999 Dec; 163(11):5843-50. PubMed ID: 10570268
[TBL] [Abstract][Full Text] [Related]
13. IL-2 during in vitro priming promotes subsequent engraftment and successful adoptive tumor immunotherapy by persistent memory phenotypic CD8(+) T cells.
Bathe OF; Dalyot-Herman N; Malek TR
J Immunol; 2001 Oct; 167(8):4511-7. PubMed ID: 11591778
[TBL] [Abstract][Full Text] [Related]
14. Low-avidity CD8lo T cells induced by incomplete antigen stimulation in vivo regulate naive higher avidity CD8hi T cell responses to the same antigen.
Maile R; Pop SM; Tisch R; Collins EJ; Cairns BA; Frelinger JA
Eur J Immunol; 2006 Feb; 36(2):397-410. PubMed ID: 16402405
[TBL] [Abstract][Full Text] [Related]
15. IL-7 is superior to IL-2 for ex vivo expansion of tumour-specific CD4(+) T cells.
Caserta S; Alessi P; Basso V; Mondino A
Eur J Immunol; 2010 Feb; 40(2):470-9. PubMed ID: 19950184
[TBL] [Abstract][Full Text] [Related]
16. Neuropilin-1 expression is induced on tolerant self-reactive CD8+ T cells but is dispensable for the tolerant phenotype.
Jackson SR; Berrien-Elliott M; Yuan J; Hsueh EC; Teague RM
PLoS One; 2014; 9(10):e110707. PubMed ID: 25343644
[TBL] [Abstract][Full Text] [Related]
17. In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire.
Ho WY; Nguyen HN; Wolfl M; Kuball J; Greenberg PD
J Immunol Methods; 2006 Mar; 310(1-2):40-52. PubMed ID: 16469329
[TBL] [Abstract][Full Text] [Related]
18. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.
Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC
Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323
[TBL] [Abstract][Full Text] [Related]
20. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function.
Filaci G; Fravega M; Negrini S; Procopio F; Fenoglio D; Rizzi M; Brenci S; Contini P; Olive D; Ghio M; Setti M; Accolla RS; Puppo F; Indiveri F
Hum Immunol; 2004 Feb; 65(2):142-56. PubMed ID: 14969769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
